DBCO-PEG4-triethoxysilane
Code | Size | Price |
---|
TAR-T17800-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T17800-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
DBCO-PEG4-triethoxysilane is a polyethylene glycol (PEG)-based linker compound that serves as an efficient building block for the synthesis of PROTACs. These PROTACs are small molecules designed to selectively target and degrade specific proteins of interest[1].
CAS:
2353410-02-1
Molecular Weight:
755.97
Purity:
0.98
SMILES:
O=C(NCCC[Si](OCC)(OCC)OCC)CCOCCOCCOCCOCCNC(=O)CCC(=O)N1C=2C=CC=CC2C#CC=3C=CC=CC3C1
References
An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562